▶ 調査レポート

帯状疱疹後神経痛治療の世界市場2023年:抗けいれん薬、貼付剤、その他

• 英文タイトル:Global Post herpetic Neuralgia Treatment Market Research Report 2023

QYResearchが調査・発行した産業分析レポートです。帯状疱疹後神経痛治療の世界市場2023年:抗けいれん薬、貼付剤、その他 / Global Post herpetic Neuralgia Treatment Market Research Report 2023 / MRC23Q36285資料のイメージです。• レポートコード:MRC23Q36285
• 出版社/出版日:QYResearch / 2023年3月
• レポート形態:英文、PDF、87ページ
• 納品方法:Eメール(2-3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥435,000 (USD2,900)▷ お問い合わせ
  Enterprise License¥870,000 (USD5,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートは世界の帯状疱疹後神経痛治療市場について調査・分析し、世界の帯状疱疹後神経痛治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析(抗けいれん薬、貼付剤、その他)、用途別セグメント分析(病院薬局、オンライン薬局、小売薬局)、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer、Arbor Pharma、Assertio Therapeutics、Endo Pharma、Teikoku Pharma、Teva、Mylan、Hengrui Medicineなどが含まれています。世界の帯状疱疹後神経痛治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX%です。COVID-19とロシア・ウクライナ戦争の影響は、帯状疱疹後神経痛治療市場規模を推定する際に考慮しました。本レポートは、帯状疱疹後神経痛治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、帯状疱疹後神経痛治療に関するビジネス上の意思決定に役立てることを目的としています。

・帯状疱疹後神経痛治療市場の概要
- 帯状疱疹後神経痛治療のタイプ別セグメント
- 世界の帯状疱疹後神経痛治療市場規模:タイプ別分析(抗けいれん薬、貼付剤、その他)
- 帯状疱疹後神経痛治療の用途別セグメント
- 世界の帯状疱疹後神経痛治療市場規模:用途別分析(病院薬局、オンライン薬局、小売薬局)
- 世界の帯状疱疹後神経痛治療市場規模予測(2018年-2029年)

・帯状疱疹後神経痛治療市場の成長トレンド
- 帯状疱疹後神経痛治療の地域別市場規模(2018年-2029年)
- 帯状疱疹後神経痛治療市場ダイナミクス
- 帯状疱疹後神経痛治療の業界動向
- 帯状疱疹後神経痛治療市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M&A動向

・タイプ別セグメント:抗けいれん薬、貼付剤、その他
- 世界の帯状疱疹後神経痛治療のタイプ別市場規模(2018年-2023年)
- 世界の帯状疱疹後神経痛治療のタイプ別市場規模(2024年-2029年)

・用途別セグメント:病院薬局、オンライン薬局、小売薬局
- 世界の帯状疱疹後神経痛治療の用途別市場規模(2018年-2023年)
- 世界の帯状疱疹後神経痛治療の用途別市場規模(2024年-2029年)

・帯状疱疹後神経痛治療の地域別市場規模
- 北米の帯状疱疹後神経痛治療市場規模(2018年-2029年)
- アメリカの帯状疱疹後神経痛治療市場規模(2018年-2029年)
- ヨーロッパの帯状疱疹後神経痛治療市場規模(2018年-2029年)
- アジア太平洋の帯状疱疹後神経痛治療市場規模(2018年-2029年)
- 中国の帯状疱疹後神経痛治療市場規模(2018年-2029年)
- 日本の帯状疱疹後神経痛治療市場規模(2018年-2029年)
- 韓国の帯状疱疹後神経痛治療市場規模(2018年-2029年)
- インドの帯状疱疹後神経痛治療市場規模(2018年-2029年)
- オーストラリアの帯状疱疹後神経痛治療市場規模(2018年-2029年)
- 中南米の帯状疱疹後神経痛治療市場規模(2018年-2029年)
- 中東・アフリカの帯状疱疹後神経痛治療市場規模(2018年-2029年)

・主要企業のプロファイル:企業情報、事業概要、売上、動向
Pfizer、Arbor Pharma、Assertio Therapeutics、Endo Pharma、Teikoku Pharma、Teva、Mylan、Hengrui Medicine

・アナリストの観点/結論

・調査方法とデータソース

Post herpetic neuralgia is a painful condition that can occur after having shingles, a complication of chicken pox. The goal of therapy for post herpetic neuralgia is to reduce morbidity through the use of tricyclic antidepressants, anticonvulsants, anesthetics, analgesics, corticosteroids and antiviral agents.
Highlights
The global Post herpetic Neuralgia Treatment market was valued at US$ 1654.8 million in 2022 and is anticipated to reach US$ 2093.9 million by 2029, witnessing a CAGR of 4.0% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Post herpetic Neuralgia Treatment key players include Pfizer, Arbor Pharma, Assertio Therapeutics, Endo Pharma, Teikoku Pharma, etc. Global top five manufacturers hold a share about 80%.
North America is the largest market, with a share over 50%, followed by Europe and China, both have a share about 30 percent.
In terms of product, Anticonvulsants is the largest segment, with a share over 80%. And in terms of distribution channel, the largest distribution channel is Hospital Pharmacies, followed by Retail Pharmacies.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Post herpetic Neuralgia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Post herpetic Neuralgia Treatment.
The Post herpetic Neuralgia Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Post herpetic Neuralgia Treatment market comprehensively. Regional market sizes, concerning products by type, by distribution channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Post herpetic Neuralgia Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by distribution channel, and by regions.
By Company
Pfizer
Arbor Pharma
Assertio Therapeutics
Endo Pharma
Teikoku Pharma
Teva
Mylan
Hengrui Medicine
Segment by Type
Anticonvulsants
Skin Patch
Other
Segment by Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, distribution channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Post herpetic Neuralgia Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by distribution channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Post herpetic Neuralgia Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Anticonvulsants
1.2.3 Skin Patch
1.2.4 Other
1.3 Market by Distribution Channel
1.3.1 Global Post herpetic Neuralgia Treatment Market Growth by Distribution Channel: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Online Pharmacies
1.3.4 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Post herpetic Neuralgia Treatment Market Perspective (2018-2029)
2.2 Post herpetic Neuralgia Treatment Growth Trends by Region
2.2.1 Global Post herpetic Neuralgia Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Post herpetic Neuralgia Treatment Historic Market Size by Region (2018-2023)
2.2.3 Post herpetic Neuralgia Treatment Forecasted Market Size by Region (2024-2029)
2.3 Post herpetic Neuralgia Treatment Market Dynamics
2.3.1 Post herpetic Neuralgia Treatment Industry Trends
2.3.2 Post herpetic Neuralgia Treatment Market Drivers
2.3.3 Post herpetic Neuralgia Treatment Market Challenges
2.3.4 Post herpetic Neuralgia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Post herpetic Neuralgia Treatment Players by Revenue
3.1.1 Global Top Post herpetic Neuralgia Treatment Players by Revenue (2018-2023)
3.1.2 Global Post herpetic Neuralgia Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Post herpetic Neuralgia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Post herpetic Neuralgia Treatment Revenue
3.4 Global Post herpetic Neuralgia Treatment Market Concentration Ratio
3.4.1 Global Post herpetic Neuralgia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Post herpetic Neuralgia Treatment Revenue in 2022
3.5 Post herpetic Neuralgia Treatment Key Players Head office and Area Served
3.6 Key Players Post herpetic Neuralgia Treatment Product Solution and Service
3.7 Date of Enter into Post herpetic Neuralgia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Post herpetic Neuralgia Treatment Breakdown Data by Type
4.1 Global Post herpetic Neuralgia Treatment Historic Market Size by Type (2018-2023)
4.2 Global Post herpetic Neuralgia Treatment Forecasted Market Size by Type (2024-2029)
5 Post herpetic Neuralgia Treatment Breakdown Data by Distribution Channel
5.1 Global Post herpetic Neuralgia Treatment Historic Market Size by Distribution Channel (2018-2023)
5.2 Global Post herpetic Neuralgia Treatment Forecasted Market Size by Distribution Channel (2024-2029)
6 North America
6.1 North America Post herpetic Neuralgia Treatment Market Size (2018-2029)
6.2 North America Post herpetic Neuralgia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Post herpetic Neuralgia Treatment Market Size by Country (2018-2023)
6.4 North America Post herpetic Neuralgia Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Post herpetic Neuralgia Treatment Market Size (2018-2029)
7.2 Europe Post herpetic Neuralgia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Post herpetic Neuralgia Treatment Market Size by Country (2018-2023)
7.4 Europe Post herpetic Neuralgia Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Post herpetic Neuralgia Treatment Market Size (2018-2029)
8.2 Asia-Pacific Post herpetic Neuralgia Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Post herpetic Neuralgia Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Post herpetic Neuralgia Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Post herpetic Neuralgia Treatment Market Size (2018-2029)
9.2 Latin America Post herpetic Neuralgia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Post herpetic Neuralgia Treatment Market Size by Country (2018-2023)
9.4 Latin America Post herpetic Neuralgia Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Post herpetic Neuralgia Treatment Market Size (2018-2029)
10.2 Middle East & Africa Post herpetic Neuralgia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Post herpetic Neuralgia Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Post herpetic Neuralgia Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Post herpetic Neuralgia Treatment Introduction
11.1.4 Pfizer Revenue in Post herpetic Neuralgia Treatment Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Arbor Pharma
11.2.1 Arbor Pharma Company Detail
11.2.2 Arbor Pharma Business Overview
11.2.3 Arbor Pharma Post herpetic Neuralgia Treatment Introduction
11.2.4 Arbor Pharma Revenue in Post herpetic Neuralgia Treatment Business (2018-2023)
11.2.5 Arbor Pharma Recent Development
11.3 Assertio Therapeutics
11.3.1 Assertio Therapeutics Company Detail
11.3.2 Assertio Therapeutics Business Overview
11.3.3 Assertio Therapeutics Post herpetic Neuralgia Treatment Introduction
11.3.4 Assertio Therapeutics Revenue in Post herpetic Neuralgia Treatment Business (2018-2023)
11.3.5 Assertio Therapeutics Recent Development
11.4 Endo Pharma
11.4.1 Endo Pharma Company Detail
11.4.2 Endo Pharma Business Overview
11.4.3 Endo Pharma Post herpetic Neuralgia Treatment Introduction
11.4.4 Endo Pharma Revenue in Post herpetic Neuralgia Treatment Business (2018-2023)
11.4.5 Endo Pharma Recent Development
11.5 Teikoku Pharma
11.5.1 Teikoku Pharma Company Detail
11.5.2 Teikoku Pharma Business Overview
11.5.3 Teikoku Pharma Post herpetic Neuralgia Treatment Introduction
11.5.4 Teikoku Pharma Revenue in Post herpetic Neuralgia Treatment Business (2018-2023)
11.5.5 Teikoku Pharma Recent Development
11.6 Teva
11.6.1 Teva Company Detail
11.6.2 Teva Business Overview
11.6.3 Teva Post herpetic Neuralgia Treatment Introduction
11.6.4 Teva Revenue in Post herpetic Neuralgia Treatment Business (2018-2023)
11.6.5 Teva Recent Development
11.7 Mylan
11.7.1 Mylan Company Detail
11.7.2 Mylan Business Overview
11.7.3 Mylan Post herpetic Neuralgia Treatment Introduction
11.7.4 Mylan Revenue in Post herpetic Neuralgia Treatment Business (2018-2023)
11.7.5 Mylan Recent Development
11.8 Hengrui Medicine
11.8.1 Hengrui Medicine Company Detail
11.8.2 Hengrui Medicine Business Overview
11.8.3 Hengrui Medicine Post herpetic Neuralgia Treatment Introduction
11.8.4 Hengrui Medicine Revenue in Post herpetic Neuralgia Treatment Business (2018-2023)
11.8.5 Hengrui Medicine Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details